NCT05944562 is a Phase 1 clinical trial of Tulmimetostat in Mycosis Fungoides, sponsored by Washington University School of Medicine.

Who is sponsoring NCT05944562?

NCT05944562 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT05944562?

Interventions in NCT05944562: Tulmimetostat.

What condition does NCT05944562 study?

NCT05944562 studies Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome.

Is NCT05944562 still recruiting?

NCT05944562 is currently active, enrolled. Last updated 11 February 2026.

Last reviewed 2026-02-11 · How we verify

NCT05944562

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Active, enrolled Phase 1 Last updated 11 February 2026

What this trial tests

Phase 1 trial testing Tulmimetostat in Mycosis Fungoides in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

9 January 2024

Primary endpoint
28 February 2027

31 January 2029

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	9 January 2024
Primary completion	28 February 2027
Estimated completion	31 January 2029
Sites	1 location across United States

Drugs / interventions tested

Tulmimetostat — full drug profile →

Conditions studied

Mycosis Fungoides — all drugs for Mycosis Fungoides →
Sezary Syndrome — all drugs for Sezary Syndrome →
Mycosis Fungoides/Sezary Syndrome — all drugs for Mycosis Fungoides/Sezary Syndrome →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Mycosis Fungoides or Sezary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth of further study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, et al · · 2024 · cited 131× · PMID 39592582 · DOI 10.1038/s41392-024-02039-0

Verify or expand the search:

Other trials of Tulmimetostat

Trials testing the same drug.

NCT07190300 — TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulm · Phase 1, PHASE2 · recruiting
NCT05467748 — EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
NCT04104776 — A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · Phase 1, PHASE2 · recruiting

Other recruiting trials for Mycosis Fungoides

Currently open trials in the same condition.

NCT07055477 — A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T- · Phase 1 · recruiting
NCT06716658 — JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Phase 2 · recruiting
NCT06207812 — Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis · recruiting
NCT06508463 — Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma · Phase 1 · recruiting
NCT04234048 — Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05944562 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 11 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05944562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing